Research Capital analyst Andre Uddin says Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:MDNA) has upcoming clinical catalysts, but he has lowered his target after removing MDNA55 partnership assumptions from his valuation. In a June 29 update, Uddin maintained his “Speculative Buy” rating on Medicenna but lowered his target to $1.60 from […]
Research Capital Corporation analyst Andre Uddin says Spectral Medical (Spectral Medical Stock Quote, Chart, News, Analysts, Financials TSX:EDT) has reached a key regulatory catalyst with the submission of its Premarket Approval application to the U.S. Food and Drug Administration for its PMX columns. In a May 29 update, Uddin maintained his “Speculative Buy” rating and […]
Share
Tweet
Share
